Fig. 4From: Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patientsEstimated overall survival in all patients from the beginning of palliative chemotherapy. The dotted lines represent point-wise 95 % confidence intervals for the survival curveBack to article page